Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Esperion Therapeutics, Inc. (ESPR : NSDQ)

• Company Description    Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol). Number of Employees: 304

• Price / Volume Information    Yesterday's Closing Price: $3.70 Daily Weekly Monthly 20 Day Moving Average: 4,574,714 shares Shares Outstanding: 239.06 (millions) Market Capitalization: $884.53 (millions) Beta: 1.04 52 Week High: $4.13 52 Week Low: $0.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.37% -2.21% 12 Week 50.71% 48.28% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3891 RANCHERO DRIVE SUITE 150 - ANN ARBOR,MI 48108 USA ph: 734-887-3903 fax: - investorrelations@esperion.com http://www.esperion.com

• General Corporate Information    Officers Sheldon L. Koenig - President; Chief Executive Officer and Director Benjamin Halladay - Chief Financial Officer J. Martin Carroll - Director Seth H.Z. Fischer - Director Alan Fuhrman - Director Peer Information Esperion Therapeutics, Inc. (GSAC) Esperion Therapeutics, Inc. (CASI) Esperion Therapeutics, Inc. (ALCD.) Esperion Therapeutics, Inc. (OMNN) Esperion Therapeutics, Inc. (CGPI.) Esperion Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 29664W105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/03/26 Share - Related Items Shares Outstanding: 239.06 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $884.53 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 3.71% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/03/26

• Fundamental Ratios P/E Current FY Estimate: 42.04 Trailing 12 Months: - PEG Ratio: 11.33 Price Ratios Price/Book: - Price/Cash Flow: 154.00 Price / Sales: 2.91 EPS Growth vs. Year Ago Period: -6.67% vs. Previous Quarter: -700.00% Sales Growth vs. Year Ago Period: 69.10% vs. Previous Quarter: 5.98% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -27.91 06/30/25 - -28.41 Current Ratio 12/31/25 - - 09/30/25 - 1.00 06/30/25 - 1.15 Quick Ratio 12/31/25 - - 09/30/25 - 0.70 06/30/25 - 0.76 Operating Margin 12/31/25 - - 09/30/25 - -31.67 06/30/25 - -35.21 Net Margin 12/31/25 - - 09/30/25 - -32.22 06/30/25 - -35.84 Pre-Tax Margin 12/31/25 - - 09/30/25 - -34.84 06/30/25 - -38.80 Book Value 12/31/25 - - 09/30/25 - -2.24 06/30/25 - -2.19 Inventory Turnover 12/31/25 - - 09/30/25 - 1.22 06/30/25 - 1.06 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©